Recent trends in praziquantel nanoformulations for helminthiasis treatment
Infections caused by parasitic flatworms impose a considerable worldwide health burden. Recently, World Health Organization launched its roadmap for neglected diseases for the period 2021 to 2030 and oral treatment with praziquantel (PZQ) in tablet form is the main drug therapy for combating these d...
Saved in:
Published in: | Expert opinion on drug delivery Vol. 19; no. 4; p. 383 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
03-04-2022
|
Subjects: | |
Online Access: | Get more information |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Infections caused by parasitic flatworms impose a considerable worldwide health burden. Recently, World Health Organization launched its roadmap for neglected diseases for the period 2021 to 2030 and oral treatment with praziquantel (PZQ) in tablet form is the main drug therapy for combating these diseases, but its use is limited by many drawbacks, including the high therapeutic dose due to the drug's low solubility and bioavailability. Among the strategies to improve PZQ performance, the use of drug nanocarriers has been cited as an interesting approach to overcome these pharmacological issues.
This review focuses on the various types of nanomaterials (polymeric, lipidic, inorganic nanoparticles, and nanocrystals) which have been recently used to improve PZQ therapy. In addition, recent advances in PZQ nanoformulations, developed to overcome the barriers of the conventional drug are described.
Considering the poor rate of discovery in the anthelmintic segment observed in recent decades, the effective management of existing drugs has become essential. The application of new strategies based on nanotechnology can extend the useful life of PZQ in new and more effective formulations. Pharmaceutical nanotechnology can solve the pharmacokinetic challenges characteristic of PZQ and improve its solubility and bioavailability. |
---|---|
AbstractList | Infections caused by parasitic flatworms impose a considerable worldwide health burden. Recently, World Health Organization launched its roadmap for neglected diseases for the period 2021 to 2030 and oral treatment with praziquantel (PZQ) in tablet form is the main drug therapy for combating these diseases, but its use is limited by many drawbacks, including the high therapeutic dose due to the drug's low solubility and bioavailability. Among the strategies to improve PZQ performance, the use of drug nanocarriers has been cited as an interesting approach to overcome these pharmacological issues.
This review focuses on the various types of nanomaterials (polymeric, lipidic, inorganic nanoparticles, and nanocrystals) which have been recently used to improve PZQ therapy. In addition, recent advances in PZQ nanoformulations, developed to overcome the barriers of the conventional drug are described.
Considering the poor rate of discovery in the anthelmintic segment observed in recent decades, the effective management of existing drugs has become essential. The application of new strategies based on nanotechnology can extend the useful life of PZQ in new and more effective formulations. Pharmaceutical nanotechnology can solve the pharmacokinetic challenges characteristic of PZQ and improve its solubility and bioavailability. |
Author | de Moraes, Josué F Longo, João Paulo Mengarda, Ana C Iles, Bruno |
Author_xml | – sequence: 1 givenname: Ana C surname: Mengarda fullname: Mengarda, Ana C organization: Research Center for Neglected Diseases, Guarulhos University, Guarulhos, Brazil – sequence: 2 givenname: Bruno surname: Iles fullname: Iles, Bruno organization: Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasília, Brasília, Brazil – sequence: 3 givenname: João Paulo surname: F Longo fullname: F Longo, João Paulo organization: Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasília, Brasília, Brazil – sequence: 4 givenname: Josué surname: de Moraes fullname: de Moraes, Josué organization: Research Center for Neglected Diseases, Guarulhos University, Guarulhos, Brazil |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35264036$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j91Kw0AUhBdR7I8-gpIXSN1z9q-9lKJVKQii1-Vkc0JXkk3Nbi_06Y2oNzPMwHwwM3Ea-8hCXIFcgFzKG3AaDWq3QIk4igHt3ImYjr0unVmpiZil9C6lsk7CuZgog1aPaSqeXthzzEUeONapCLE4DPQVPo4UM7dFpNg3_dAdW8qhj6kYQ7Hntgsx7wOlkH6WlLuRcSHOGmoTX_75XLzd372uH8rt8-ZxfbstvbI2l9AQg3SuqcB5YytPTAqkBFh5sr6xnpErRmuwYaiXWtMSmWqGSilTI87F9S_3cKw6rneHIXQ0fO7-T-E3zo5R0Q |
CitedBy_id | crossref_primary_10_3923_bj_2023_1_7 crossref_primary_10_1128_spectrum_01393_23 crossref_primary_10_1128_spectrum_01807_22 crossref_primary_10_1128_aac_00114_24 crossref_primary_10_2217_nnm_2023_0027 crossref_primary_10_3390_ma16093382 crossref_primary_10_3390_pharmaceutics14102023 crossref_primary_10_1002_wnan_1852 crossref_primary_10_1007_s11356_022_23098_2 crossref_primary_10_3390_pharmaceutics15071910 crossref_primary_10_1021_acsomega_3c06111 crossref_primary_10_1021_acsnano_4c00014 crossref_primary_10_3390_nano12101683 crossref_primary_10_3762_bjnano_15_2 crossref_primary_10_2217_nnm_2022_0228 crossref_primary_10_2174_1574885518666230403111528 crossref_primary_10_3389_fphar_2022_917363 crossref_primary_10_4155_fmc_2023_0152 crossref_primary_10_1038_s41598_022_23110_2 crossref_primary_10_3389_fphar_2022_901459 crossref_primary_10_1016_j_ejmech_2023_115268 crossref_primary_10_3390_pharmaceutics15061583 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1080/17425247.2022.2051477 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1744-7593 |
ExternalDocumentID | 35264036 |
Genre | Journal Article Review |
GroupedDBID | --- 00X 03L 0BK 0R~ 29G 4.4 53G 5GY AAMIU AAOUU AAPWH ABBAB ABEIZ ABJNI ABJYH ABLIJ ABLKL ABVAX ABXYU ACGFS ACIEZ ADCVX ADRBQ ADTOD AECIN AENEX AEOZL AGDLA AGMLL AIJEM AIRBT AIYSM AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU BABNJ BLEHA CAZVN CCCUG CGR CS3 CUY CVF DASJU DAWQK DKSSO DU5 EBS ECM EIF EJD F5P H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M44 M4Z NPM O9- P2P RNANH TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ TZHSB V1S ~1N |
ID | FETCH-LOGICAL-c366t-1fae1077fb17c56bcaea3100119ca6cf6ce2ebe2652fe1d844a82eade1b335d22 |
IngestDate | Wed Oct 16 00:41:16 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | nanoformulation oral formulation drug discovery pediatric formulation nanotechnology parasitic diseases helminthiasis nanomaterials schistosomiasis Nanomedicine |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c366t-1fae1077fb17c56bcaea3100119ca6cf6ce2ebe2652fe1d844a82eade1b335d22 |
PMID | 35264036 |
ParticipantIDs | pubmed_primary_35264036 |
PublicationCentury | 2000 |
PublicationDate | 2022-04-03 |
PublicationDateYYYYMMDD | 2022-04-03 |
PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-03 day: 03 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Expert opinion on drug delivery |
PublicationTitleAlternate | Expert Opin Drug Deliv |
PublicationYear | 2022 |
SSID | ssj0036701 |
Score | 2.49657 |
SecondaryResourceType | review_article |
Snippet | Infections caused by parasitic flatworms impose a considerable worldwide health burden. Recently, World Health Organization launched its roadmap for neglected... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 383 |
SubjectTerms | Anthelmintics - chemistry Anthelmintics - therapeutic use Biological Availability Helminthiasis - drug therapy Humans Praziquantel - pharmacology Praziquantel - therapeutic use Solubility |
Title | Recent trends in praziquantel nanoformulations for helminthiasis treatment |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35264036 |
Volume | 19 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELYSkKpeEK9SnvKh6mW7JfZ617tHVIIAUVSJVOqt8q7tNFLqDWn20P76zqyzj4aC4MDFSuzIG3m-TMaez_MRsscim1uZZqGKMx4KyZMwF1kUxtJqxQrLRnktYvtDfj9LP47FeDBoJLi6vv9qaegDW-PN2X-wdjspdMBrsDm0YHVo_8ruEAdien_Vcl0XS3Uz-1nhCs4Dp1yJYWrVUOCQZXhh5pczt7qYKaxO0lLP7xzaY0XkVYC3q-oI0wV6WU0DbebI6-iYxMZNAXL-rNap7gj2y1paGwsdlC1mgm-lm_rUT1ln7KOypiq2n9DodJbKNMmKyuf1-0cVsMtFhot3X8a7VylEKGOvidj636yHM9FzppGXuPnFyXtWJMzFYy7kIT4JGoj8vCBMz8iLy9rKqAEgRr7Qyp9HN2pvN0NDMoRICoPto-Pmfx4r37HmTlg6en_v99kmW80cG_uWOn6ZPCaP1hsP-sEj5gkZGPeU7J_4yuXXB3TSXcS7OqD79KSraX79jHz1sKIeVnTmaB9WdBNWFN7QO7CiLayek9NP48nR53AtwxEWUZKsQmaVYSMpbc5kESd5oYzCtBBjWaGSwqKmHLgCnsTcGqZTIVTKkYfP8iiKNec75IErndkl1GQ5BE1xoSFoFQXTKF6aGpGj_gtSAF6SF36Nzhe-1sp5s3qvfjvymmx3WHtDHlr4IZu3ZHilq3e1wW4Bb09oaQ |
link.rule.ids | 782 |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recent+trends+in+praziquantel+nanoformulations+for+helminthiasis+treatment&rft.jtitle=Expert+opinion+on+drug+delivery&rft.au=Mengarda%2C+Ana+C&rft.au=Iles%2C+Bruno&rft.au=F+Longo%2C+Jo%C3%A3o+Paulo&rft.au=de+Moraes%2C+Josu%C3%A9&rft.date=2022-04-03&rft.eissn=1744-7593&rft.volume=19&rft.issue=4&rft.spage=383&rft_id=info:doi/10.1080%2F17425247.2022.2051477&rft_id=info%3Apmid%2F35264036&rft_id=info%3Apmid%2F35264036&rft.externalDocID=35264036 |